Announcements Trials
Browse Landscape

Status

No longer available 4Approved for marketing 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Expanded_access 5Interventional 1

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 5Myasthenic Syndromes, Congenital 2

Interventions

3-Iodobenzylguanidine 6Magnetic Resonance Spectroscopy 5Amifampridine 5gallium 68 PSMA-11 4fludarabine phosphate 3Cyclophosphamide 3pembrolizumab 2fluorodopa F 18 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Oxaliplatin 2Ga(III)-DOTATOC 2Fluorouracil 2Bortezomib 2Bone Marrow Transplantation 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1motexafin gadolinium 1mifamurtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Expanded_access × Amifampridine × Clear all
NCT00872950 2022-04-11

LEMS

Lahey Clinic

Approved for marketing

Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

NCT02012933 2019-12-11

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Oregon Health and Science University

No longer available

Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

NCT00704925 2019-10-30

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

University of California, Davis

No longer available

Lambert-Eaton Myasthenic Syndrome

NCT00994916 2019-07-09

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

University of Pittsburgh

No longer available

Lambert-Eaton Myasthenic Syndrome

NCT01378546 2013-07-18

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Columbia University

No longer available

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡